Board of Directors

Andrew Dreyfus, President and Chief Executive Officer for Blue Cross Blue Shield of Massachusetts

Mr. Dreyfus has served as president and chief executive officer for Blue Cross Blue Shield of Massachusetts, or BCBSMA, one of the largest Blue Cross Blue Shield insurance plans in the country, since 2010. From 2005 to 2010, Mr. Dreyfus served as the executive vice president of healthcare services of BCBSMA. Prior to joining BCBSMA, he served as the first president of the Blue Cross Blue Shield Foundation. Mr. Dreyfus also previously served as executive vice president of the Massachusetts Hospital Association and held a number of senior positions in Massachusetts state government, including undersecretary of consumer affairs and business regulation. Mr. Dreyfus serves on the board of directors of BCBSMA, the Blue Cross Blue Shield Association, Boys & Girls Clubs of Boston and RIZE Massachusetts. He is a member of the advisory boards of Ariadne Labs and the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California (USC). He is a founding member of the Massachusetts Coalition for Serious Illness Care. Mr. Dreyfus received a B.A. in English from Connecticut College.

Julie H. McHugh, Chair - Former Chief Operating Officer, Endo Health Solutions, Inc.

Ms. McHugh most recently served as chief operating officer for Endo Health Solutions, Inc., or Endo, from 2010 through 2013, where she was responsible for the specialty pharmaceutical and generic drug businesses. Prior to joining Endo, Ms. McHugh was the chief executive officer of Nora Therapeutics, Inc. Before that she served as company group chairman for the worldwide virology business unit of Johnson & Johnson, or J&J, and previously she was president of Centocor, Inc., a J&J subsidiary. While at J&J, Ms. McHugh oversaw the development and launches of several products, including Remicade® (infliximab), Prezista® (darunavir) and Intelence® (etravirine), and she was responsible for oversight of a research and development portfolio including compounds targeting HIV, hepatitis C, and tuberculosis. Prior to joining Centocor, Inc., Ms. McHugh led the marketing communications for gastrointestinal drug Prilosec® (omeprazole) at AstraMerck Inc. Ms. McHugh currently serves on the board of directors of Trevena, Inc. (with such service to end in connection with Trevena, Inc.’s 2021 annual meeting of stockholders), Aerie Pharmaceuticals, Inc. and Lantheus Holdings, Inc. She also serves on the board of directors of Evelo Biosciences, Inc., including serving as chair of the nominating and corporate governance committee and as a member of the audit committee. She also chairs the board of visitors for the Smeal College of Business of Pennsylvania State University as well as serves on the board of directors of The New Xellia Group. She previously served on the board of directors for ViroPharma Inc., Epirus Biopharmaceuticals, Inc., the Biotechnology Industry Organization, the Pennsylvania Biotechnology Association and the New England Healthcare Institute. Ms. McHugh received her M.B.A. degree from St. Joseph’s University and her B.S. degree from Pennsylvania State University.

Edward P. Owens, Former Partner, Portfolio Manager and Global Industry Analyst, Wellington Management Company, LLP

Mr. Owens was previously partner, portfolio manager and global industry analyst with Wellington Management Company, LLP where he worked in investment management from 1974 to 2012. He was the portfolio manager of the Vanguard Health Care Fund for 28 years from its inception in May 1984 until his retirement from Wellington in December 2012. Mr. Owens serves on the board of directors of Stealth BioTherapeutics Corp and ESCAPE Bio. He has a B.S. in physics from the University of Virginia and an M.B.A. from Harvard Business School.

Mark G. Currie, Ph.D., Former President and Chief Scientific Officer, Cyclerion Therapeutics, Inc.


Dr. Currie has served as a senior advisor to Cyclerion Therapeutics, Inc., or Cyclerion, a clinicalstage biopharmaceutical company, since January 2021. Dr. Currie previously served as Cyclerion’s president and chief scientific officer from April 2019 to December 2020, and, prior to that, served as senior vice president, chief scientific officer and president of research and development at Ironwood from 2002 to April 2019. Prior to joining Ironwood, Dr. Currie directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor, Inc. and initiated, built and led discovery pharmacology and also served as director of arthritis and inflammation at Monsanto Company. Dr. Currie currently serves on the board of directors of Science Exchange LLC. Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman Gray School of Medicine of Wake Forest University.

Read about Mark’s inspiration to become a drug hunter

Jon R. Duane, Senior Partner Emeritus, McKinsey & Company

Mr. Duane is senior partner emeritus at McKinsey & Company, or McKinsey, an international management consulting company. Before his retirement in December 2017, Mr. Duane had served as a partner at McKinsey since 1992. At McKinsey, Mr. Duane founded and led the firm’s biotech practice. In that role, Mr. Duane advised both private and public companies in the pharmaceutical, medical device and life science industries, as well as academic research centers, on various strategic initiatives. Mr. Duane serves as the executive chair on the board of Nashville Biosciences. Mr. Duane graduated from Wesleyan University with a B.A. in government and received an M.B.A from Harvard Business School.

Marla L. Kessler, Chief Customer Officer, Aetion, Inc.

Marla Kessler joined our board of directors in April 2019. Ms. Kessler currently serves as chief customer officer of Aetion, Inc., or Aetion. Prior to joining Aetion, Ms. Kessler served as an advisor to the chief executive officer of IQVIA Holdings, Inc., or IQVIA (formerly IMS Health and Quintiles), from 2020 to 2021. Prior to that, Ms. Kessler had been the senior vice president for strategy, marketing and communications for IQVIA from 2016 to 2020. Previously, Ms. Kessler served in various roles for IQVIA, including vice president for global services marketing and knowledge management from 2013 to 2016, regional leader of the IMS Consulting Group in Europe from 2011 to 2013, location manager for the London IMS Consulting Group from 2009 to 2011 and senior principal from 2008 to 2009. Before joining IQVIA, Ms. Kessler led several marketing efforts for Pfizer, Inc. from 2004 to 2007 and worked in consulting for McKinsey & Company from 1996 to 2004. Ms. Kessler received a B.S. in economics from Arizona State University and an M.B.A. from the Fuqua School of Business at Duke University.

Catherine Moukheibir, Former Chief Executive Officer, MedDay Pharmaceuticals

Catherine Moukheibir joined our board of directors in April 2019. Ms. Moukheibir most recently served as chief executive officer, as well as chairman of the board of directors, of MedDay Pharmaceuticals. Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA from March 2011 to December 2016 and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired. Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007. Ms. Moukheibir also serves on the board of directors of Asceneuron SA, Biotalys NV, DNA Script, Noema Pharma, Orphazyme A/S and CMR Surgical Ltd. She also held past directorships on the boards of directors of Ablynx NV, Cerenis Therapeutics SA, Creabilis S.A., GenKyoTex S.A., Kymab Group Limited, and Zealand Pharma A.S. Ms. Moukheibir received a M.A. in economics and an M.B.A. from Yale University.

Lawrence S. Olanoff, M.D., Ph.D., Former Chief Operating Officer, Forest Laboratories, Inc.

Dr. Olanoff most recently served as chief operating officer for Forest Laboratories, Inc., or Forest, (acquired by Allergan plc) from 2006 to 2010. Dr. Olanoff also served as a director of Forest from 2006 to 2014. From 2005 to 2006, Dr. Olanoff was president and chief executive officer and a director at Celsion Corporation. He also served as executive vice president and chief scientific officer of Forest from 1995 to 2005. Prior to joining Forest in 1995, Dr. Olanoff served as senior vice president of clinical research and development at Sandoz Pharmaceutical Corporation (now a division of the Novartis Group) and at the Upjohn Company in a number of positions, including corporate vice president of clinical development and medical affairs. In addition, he is currently an adjunct assistant professor and special advisor to the president for corporate relations at the Medical University of South Carolina (MUSC), an exofficio director of the MUSC Foundation for Research Development, chairman of the board of directors of Mitochondria in Motion, chairman of TAC Development LLC, chairman of the Elliot and Eleanor Foundation and a member of the board of directors of Clinical Biotechnology Research Institute at Roper St. Francis Hospital, the Westedge Project, Ichnos Sciences, and the Zucker Institute for Applied Neurosciences. Dr. Olanoff also held past directorships on the boards of directors of Axovant Sciences Ltd. and Celsion Corporation. Dr. Olanoff received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University.

Alexander J. Denner, Ph.D., Founding Partner and Chief Investment Officer, Sarissa Capital Management LP

Alexander Denner joined our board of directors in October 2020. Dr. Denner is a founding partner and chief investment officer of Sarissa Capital Management LP, or Sarissa, where he has been since 2011. Sarissa Capital focuses on improving the strategies of companies to enhance shareholder value. Dr. Denner is also the chair of the board of directors and chief executive officer of Sarissa Capital Acquisition Corp. From 2006 to 2011, Dr. Denner served as a senior managing director at Icahn Capital L.P. Prior to that, he served as a portfolio manager at Viking Global Investors and Morgan Stanley Investment Management. Dr. Denner currently serves on the board of directors of Biogen Inc. and Attralus, Inc. In the last five years, Dr. Denner has served as chair of the board of directors of Ariad Pharmaceuticals, Inc. and The Medicines Company, as well as a member of the board of directors of Bioverativ Inc. Dr. Denner received an S.B. in mechanical engineering from Massachusetts Institute of Technology, an M.S. and M. Phil in mechanical engineering from Yale University, and an interdisciplinary Ph.D, also from Yale University.

Jay P. Shepard, Former President and Chief Executive Officer of Aravive, Inc.

Mr. Shepard was president and chief executive officer of Aravive, Inc. (formerly Versartis, Inc.), a clinicalstage oncology company, from May 2015 to January 2020, and has served as a member of its board of directors since 2013 and as chairman of its board of directors since January 2020. From 2012 until May 2015, Mr. Shepard was an executive partner at Sofinnova Ventures, a venture capital firm focused on the healthcare industry, which he joined as an executive in residence in 2008. From 2010 to 2012, Mr. Shepard served as president and chief executive officer and was a member of the board of directors of NextWave Pharmaceuticals, Inc., a specialty pediatric pharmaceutical company. From 2005 to 2007, Mr. Shepard served as president and chief executive officer and a member of the board of directors of Ilypsa, Inc. (acquired by Amgen Inc.), a biopharmaceutical company focused on therapies for renal and metabolic disorders. Mr. Shepard currently serves on the board of directors of Inovio Pharmaceuticals, Inc., Esperion Therapeutics, Inc. and the Christopher & Dana Reeve Foundation. Within the past five years, Mr. Shepard also served on the boards of directors of Marinus Pharmaceuticals, Inc. and Durect Corporation. Mr. Shepard holds a B.S. in Business Administration from the University of Arizona.

Thomas McCourt, Chief Executive Officer, Ironwood Pharmaceuticals, Inc.

Tom McCourt joined Ironwood in 2009. Mr. McCourt has served as our chief executive officer and member of the board of directors since June 2021 and had served as president and interim chief executive officer from February 2021 to June 2021. Mr. McCourt had served as president from April 2019 to June 2021. Prior to April 2019, Mr. McCourt had served as our senior vice president of marketing and sales and chief commercial officer since joining Ironwood in 2009. Prior to joining Ironwood, Mr. McCourt led the U.S. brand team for denosumab at Amgen Inc. from April 2008 to August 2009. Prior to that, Mr. McCourt was with Novartis AG from 2001 to 2008, where he directed the launch and growth of ZELNORM™ for the treatment of patients with IBS-C and CIC and held a number of senior commercial roles, including vice president of strategic marketing and operations. Mr. McCourt was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and then serving as brand manager for PRILOSEC® and NEXIUM®. Mr. McCourt serves on the board of directors, including on the audit and compensation committees, of Acceleron Pharma Inc. and has a degree in pharmacy from the University of Wisconsin.